In a study conducted by Zhou et al., it was observed that SGLT2 inhibitors (dapagliflozin and canagliflozin) manifested an anti-proliferative impact on breast cancer cells both in vitro and in vivo (utilizing nude mouse xenograft growth models). Here, SLC5A2 is linked to breast carcinoma.